For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
Plasminogen activator Inhibitor Type 1 Human Chromogenic Activity Kit (ab108894) has been developed to determine human type I plasminogen activator inhibitor (PAI-1) activity in cell culture supernatants. A fixed amount of tissue-type plasminogen activator (tPA) is added in excess to undiluted sample, which allows PAI-1 and tPA to form an inactive complex. The assay measures plasminogen activation by residual tPA in coupled assays that contain tPA, plasminogen, and a plsmin-specific synthetic substrate. The amount of plasmin produced is quantitated using a highly specific plasmin substrate releasing a yellow para-nitroaniline (pNA) chromophore. The absorbance of the pNA at 405 nm is inversely proportional to the PAI-1 enzymatic activity.
Type I plasminogen activator inhibitor (PAI-1) is a 50 kDa serpin family member that inhibits tissue- and urokinase-type plaminogen activators (t-PA, u-PA). This protein appears to be an important regulator of plasminogen activation by t-PA and extracellular proteolysis by u-PA. The plasminogen activator proteolytic enzyme systems are important not only for fibrinolysis but also for extracellular matrix remodeling, and have been implicated in a number of normal and pathological processes including angiogensis, ovulation and embryogenesis, thrombotic and hemorrhagic disorders, connective tissue diseases, neoplasm and sepsis. PAI-1 is a prognosticator in breast cancer, gastric cancer, various forms of lung cancer and cervical cancer.
|Assay Diluent||1 x 30ml|
|Human Plasminogen||1 vial|
|Plasmin Substrate||2 vials|
|Sealing Tapes||3 units|
|tPA Standard 30IU||1 vial|
Our Abpromise guarantee covers the use of ab108894 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Functional Studies||Use at an assay dependent dilution.|
ab108894 has not yet been referenced specifically in any publications.